Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2007

Cet article est inclus dans 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
  • EINSTEIN DVT [Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis] (8 documents)
This article is part of the following matrixes of evidence:
Loading references information
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).
Epistemonikos ID: 9a7d7ba74ee3c9b2732e14b24e3b66ef9604c462
First added on: Jan 21, 2016